CD274 and non-small cell lung carcinoma: Moreover, the KEYNOTE-189 and KEYNOTE-407 studies also demonstrated that the first-line combination of pembrolizumab and chemotherapy provided longer OS benefits in advanced-stage NSCLC regardless of PD-L1 expression level [9,10].